Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Articles published by Vertex Pharmaceuticals Incorporated < Previous 1 2 3 4 Next > Health Canada Grants Marketing Authorization for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in Children With Cystic Fibrosis Ages 6 Through 11 years With At Least One F508del Mutation April 20, 2022 From Vertex Pharmaceuticals Incorporated Via Business Wire Tickers VRTX Vertex Announces Statistically Significant and Clinically Meaningful Results From Two Phase 2 Proof-of-Concept Studies of VX-548 for the Treatment of Acute Pain March 31, 2022 From Vertex Pharmaceuticals Incorporated Via Business Wire Tickers VRTX Vertex Announces Reimbursement Agreement in Australia for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) for Patients With Cystic Fibrosis Ages 12 Years and Older With at Least One F508del Mutation in the CFTR Gene March 26, 2022 From Vertex Pharmaceuticals Incorporated Via Business Wire Tickers VRTX Vertex Advances VX-147 Into Pivotal Clinical Development for People With APOL1-Mediated Kidney Disease March 22, 2022 From Vertex Pharmaceuticals Incorporated Via Business Wire Tickers VRTX Vertex Reports Fourth Quarter 2021 and Full Year Financial Results January 26, 2022 From Vertex Pharmaceuticals Incorporated Via Business Wire Tickers VRTX Vertex to Announce Fourth Quarter 2021 Financial Results on January 26 January 18, 2022 From Vertex Pharmaceuticals Incorporated Via Business Wire Tickers VRTX European Commission Approves KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) in Combination With Ivacaftor to Treat Children With Cystic Fibrosis Ages 6 to 11 Years January 11, 2022 From Vertex Pharmaceuticals Incorporated Via Business Wire Tickers VRTX Vertex to Present at the 40th Annual J.P. Morgan Healthcare Conference on January 10 January 04, 2022 From Vertex Pharmaceuticals Incorporated Via Business Wire Tickers VRTX Vertex Announces Positive Results From Phase 2 Study of VX-147 in APOL1-Mediated Focal Segmental Glomerulosclerosis December 01, 2021 From Vertex Pharmaceuticals Incorporated Via Business Wire Tickers VRTX Vertex Announces Reimbursement Agreement in Spain for KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) in Combination With Ivacaftor to Treat People With Cystic Fibrosis 12 Years and Older With At Least One F508del Mutation in the CFTR Gene November 19, 2021 From Vertex Pharmaceuticals Incorporated Via Business Wire Tickers VRTX Vertex Receives CHMP Positive Opinion for KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) in Combination With Ivacaftor in Children With Cystic Fibrosis Ages 6 Through 11 November 12, 2021 From Vertex Pharmaceuticals Incorporated Via Business Wire Tickers VRTX Vertex Reports Third-Quarter 2021 Financial Results November 02, 2021 From Vertex Pharmaceuticals Incorporated Via Business Wire Tickers VRTX Vertex to Announce Third-Quarter 2021 Financial Results on November 2 October 22, 2021 From Vertex Pharmaceuticals Incorporated Via Business Wire Tickers VRTX Vertex to Present Long-Term Data Demonstrating Significant Benefits of Treatment With CFTR Modulators at North American Cystic Fibrosis Conference (NACFC) October 19, 2021 From Vertex Pharmaceuticals Incorporated Via Business Wire Tickers VRTX Vertex Announces Positive Day 90 Data for the First Patient in the Phase 1/2 Clinical Trial Dosed With VX-880, a Novel Investigational Stem Cell-Derived Therapy for the Treatment of Type 1 Diabetes October 18, 2021 From Vertex Pharmaceuticals Incorporated Via Business Wire Tickers VRTX Vertex to Present at the Morgan Stanley Virtual 19th Annual Global Healthcare Conference on September 15th September 13, 2021 From Vertex Pharmaceuticals Incorporated Via Business Wire Tickers VRTX Vertex Announces Publication in The New England Journal of Medicine of Phase 3 Results for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in People With Cystic Fibrosis August 26, 2021 From Vertex Pharmaceuticals Incorporated Via Business Wire Tickers VRTX Vertex Appoints Stuart A. Arbuckle as Chief Operating Officer August 04, 2021 From Vertex Pharmaceuticals Incorporated Via Business Wire Tickers VRTX Vertex Reports Second-Quarter 2021 Financial Results July 29, 2021 From Vertex Pharmaceuticals Incorporated Via Business Wire Tickers VRTX Vertex to Initiate Phase 3 Development Program for New Once-Daily Triple Combination Regimen in People With Cystic Fibrosis July 28, 2021 From Vertex Pharmaceuticals Incorporated Via Business Wire Tickers VRTX Vertex Initiates Phase 2 Clinical Trial Program for VX-548 for the Treatment of Acute Pain July 19, 2021 From Vertex Pharmaceuticals Incorporated Via Business Wire Tickers VRTX Vertex to Announce Second-Quarter 2021 Financial Results on July 29 July 16, 2021 From Vertex Pharmaceuticals Incorporated Via Business Wire Tickers VRTX Vertex Announces National Reimbursement Agreement in France for KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) and SYMKEVI® (tezacaftor/ivacaftor) for Eligible Cystic Fibrosis Patients June 28, 2021 From Vertex Pharmaceuticals Incorporated Via Business Wire Tickers VRTX Vertex Announces New Portfolio Reimbursement Agreement in Italy Including KAFTRIO®, SYMKEVI® and Additional Indications of ORKAMBI® and KALYDECO® for Eligible Patients With Cystic Fibrosis June 25, 2021 From Vertex Pharmaceuticals Incorporated Via Business Wire Tickers VRTX Health Canada Grants Marketing Authorization for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in People Ages 12 and Older Who Have at Least One F508del Mutation June 18, 2021 From Vertex Pharmaceuticals Incorporated Via Business Wire Tickers VRTX Vertex and CRISPR Therapeutics Present New Data in 22 Patients With Greater Than 3 Months Follow-Up Post-Treatment With Investigational CRISPR/Cas9 Gene-Editing Therapy, CTX001™ at European Hematology Association Annual Meeting June 11, 2021 From Vertex Pharmaceuticals Incorporated Via Business Wire Tickers CRSP VRTX Vertex Announces Primary Endpoint Achieved in Phase 2 Study of VX-864 in Alpha-1 Antitrypsin Deficiency June 10, 2021 From Vertex Pharmaceuticals Incorporated Via Business Wire Tickers VRTX CORRECTING and REPLACING Vertex Announces U.S. FDA Approval for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in Children With Cystic Fibrosis Ages 6 through 11 With Certain Mutations June 09, 2021 From Vertex Pharmaceuticals Incorporated Via Business Wire Tickers VRTX Vertex Announces U.S. FDA Approval for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in Children With Cystic Fibrosis Ages 6 through 11 With Certain Mutations June 09, 2021 From Vertex Pharmaceuticals Incorporated Via Business Wire Tickers VRTX Vertex to Present at the Bank of America Securities 2021 Virtual Health Care Conference on May 13 May 10, 2021 From Vertex Pharmaceuticals Incorporated Via Business Wire Tickers VRTX < Previous 1 2 3 4 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.